There’s a good chance a Procter & Gamble (NYSE:PG) product touched your morning before coffee did. Tide, Pampers, Gillette, Crest, Charmin, Olay: the company sells the everyday stuff that sits in bathroom cabinets and laundry rooms across the world. That reach turned into $87.0 billion of net sales in fiscal 2026.
Here’s the tension. For years, investors paid a premium for that predictability. Now P&G’s growth has slowed to a crawl, and the stock trades below its own historical valuation. Even with that valuation pullback, the household products giant fails to land a spot among the 10 Best Undervalued Stocks to Buy in October. Whether that discount is an opening or an honest repricing depends on one thing: can a company this large get volumes moving again while costs push the other way?
Pricing Power, Under Strain
P&G’s edge has always been scale. It spends heavily on advertising and research, wins shelf space retailers can’t afford to give lesser brands, and then raises prices without losing many shoppers. Fiscal 2026 showed that muscle still works, but barely. Organic sales (growth that strips out currency swings, acquisitions, and divestitures) rose 1%, and all of it came from pricing. Volume and mix contributed nothing.
The company still throws off serious cash. Adjusted free cash flow productivity (the share of earnings converted into free cash) came in at 100%, and P&G returned over $15 billion to shareholders, including $10.2 billion in dividends and $5.0 billion in buybacks. The dividend went up for the 70th straight year, extending a payout streak that’s now 136 years long, which keeps P&G firmly among the market’s top 11 Dividend Kings to buy for safe dividend growth.
A Year of Foundation Building
The fiscal fourth quarter told the story in miniature. Net sales rose 2% to $21.2 billion, but organic sales were flat. Core earnings per share (P&G’s adjusted measure, which strips out restructuring costs) slipped 3% to $1.43.
Under the surface, the segments split. Beauty grew organic sales 4%, a genuine bright spot. Baby, Feminine & Family Care went the other way, with organic sales down 2%, and Health Care slipped 1%. Those are categories where shoppers can trade down to store brands, a pressure that other big household-products makers are wrestling with too.
CEO Shailesh Jejurikar described fiscal 2026 as a year spent laying groundwork while still growing sales and profit. Part of that groundwork is a restructuring plan expected to cost roughly $1 billion to $1.6 billion before tax over two years, trimming the portfolio and reworking the supply chain. More than half of those charges landed in fiscal 2026.
Is the Reacceleration Running Late?
That’s the worry investors keep circling. P&G’s fiscal 2027 guidance calls for organic sales growth of 1% to 3% and core EPS growth from flat to 3%, or $6.89 to $7.11 a share. Behind that cautious range sits a heavy cost bill: about $1 billion after tax from higher raw material, energy, and transportation costs. Add higher interest expense, lower non-operating income, and currency, and the company pegs the total hit at $0.56 a share, an 8% drag on core EPS growth.
Fiscal 2026 margins already showed the strain, with gross margin down 100 basis points to 50.2%. If pricing can’t cover another round of inflation, P&G may have to choose between protecting margins and protecting volumes. Still, guidance that grows earnings at all despite an 8% drag suggests the underlying business is doing more than the headline shows.
What the Market Is Paying
At 21.67 times forward earnings, as of October 12, P&G trades below its 5-year historical average P/E of 23.84. Put plainly, investors are paying less for each dollar of expected profit than in a typical recent year. A discount to its own past only tells half the story, though. The sector P/E sits at 14.56, so P&G still carries a hefty premium over consumer staples peers trading at lower multiples. That premium was earned through reliability.
The growth outlook makes the trade-off clearer. Analysts expect EPS growth of 5.99% in 2028, faster than the flat-to-3% range P&G is guiding for fiscal 2027. If that recovery shows up, today’s multiple looks reasonable for a business of this quality. If growth stays stuck near fiscal 2026’s pace, the stock’s slide below its historical average starts to look less like a discount and more like the new normal. Short interest is just 1.05% of the float, a sign that bearish bets on the stock remain limited even as growth has stalled.
The Discount Has a Condition Attached
P&G’s moat hasn’t cracked, but it isn’t widening either. Pricing works, cash flows, and the dividend streak is intact. What’s missing is volume. For patient, income-minded investors who value durability over speed, the setup looks more reasonable than it has in some time. The signal to watch is volume: a return to positive volume growth as restructuring winds down would support the case for a higher multiple. Another year of pricing-only growth, with margins still sliding, would argue that the lower valuation is deserved.
While we acknowledge the risk and potential of PG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PG and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Top 10 AI Stocks That Will Skyrocket and 2 Stocks Trump Bought in July Are Now Down 17% to 20%. Time to Buy?
